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Objective: This study aimed to describe and compare the nutritional status of adult patients
submitted to allogeneic hematopoietic stem cell transplantation at two different time points
(admission and discharge).
Methods: A retrospective, descriptive and quantitative study was performed based on clini-
cal,  laboratory and nutritional data obtained from medical records of adult patients of both
genders submitted to allogeneic hematopoietic stem cell transplantation in a bone marrow
transplantation reference center in Rio de Janeiro in the period from 2010 to 2013. Statistical
analysis was performed using the SPSS software (version 22.0).
Results: Sixty-four patients were evaluated. The mean age was 42.1 ± 3.2 years and the
most prevalent disease was acute myeloid leukemia (39%). There was a high prevalence
of  gastrointestinal symptoms including nausea (100%), vomiting (97%) and mucositis (93%).
Between admission and discharge there was a signiﬁcant decrease in the median weight
(−2.5  kg; 71.5 vs. 68.75 kg; p-value < 0.001), body mass index (−0.9 kg/m2; 24.8 vs. 24.4 kg/m2;
p-value < 0.001), and serum albumin levels (−0.2 g/dL; 3.7 vs. 3.6 g/dL; p-value = 0.024). The
survival time after hematopoietic stem cell transplantation correlated negatively with C-
reactive protein at discharge (CC = −0.72; p-value < 0.001) and positively with serum albumin
levels  (CC = 0.56; p-value = 0.004) and with high total protein level at discharge (CC = 0.53;
p-value = 0.006).
Conclusion: Our results suggest that patients submitted to allogeneic hematopoietic stem
cell  transplantation have compromised nutritional status during the hospital stay for trans-
plantation.©  2014 Associac¸ão Bra
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ntroduction
ematopoietic stem cell transplantation (HSCT) is a highly
omplex procedure indicated for the treatment of various
iseases, including aggressive hematological, oncohemato-
ogical, and genetic diseases and autoimmune disorders.
SCT involves an intravenous infusion of hematopoietic stem
ells (HSC) used to restore bone marrow function. Allogeneic
SCT uses hematopoietic stem cells (HSC) either from related
r unrelated donors.1,2
The conditioning regimen is intended to eradicate resid-
al disease of the patient and, in the case of allogeneic HSCT,
o induce immunosuppression to allow engraftment of the
nfused HSC.3,4
The aggressive conditioning regimen used for allogeneic
SCT may combine chemotherapy with total body irradiation
TBI). A large number of clinical complications is associated
ith this type of transplantation; the morbidity and mortality
re mainly associated to opportunistic infections, graft versus
ost disease (GVHD), organ failure, graft failure or rejection
nd relapse of the underlying disease.5,6
Patients submitted to allogeneic HSCT should be con-
idered at nutritional risk7–9 due to reduced energy intake,
mpaired absorption of nutrients and increased metabolic
emands.10
The adverse effects of chemotherapy and TBI affect, in par-
icular, the gastrointestinal (GI) tract and the immune system.7
ccordingly, in addition to symptoms of nausea and vomi-
ing, severe mucositis associated with intense odynophagia,
bdominal pain and diarrhea often occurs.11,12 GI complica-
ions of the conditioning regimen may last for up to 21 days
fter transplantation.8,10
HSC transplant patients are likely to develop a series
f metabolic disorders of varying severity, mostly during
he immediate post-transplant period. The main causes are
he adverse effects of the conditioning regimen itself, the
mmunosuppressive drugs (to control or for prophylaxis of
VHD) and the total parenteral nutrition (TPN), which may
ncrease the risk of opportunistic infections and inﬂammatory
rocesses.13
GVHD is one of the most important clinical complications
elated to allogeneic HSCT. It is related to an immune response
riggered by the donor HSC cells against the host tissues which
sually involves the liver, skin and the GI tract. Acute diar-
hea in the post-transplant period is usually associated with
nfections and GVHD.8,12,14
The present study aimed to compare the nutritional status
f adult allogeneic HSCT patients at two different time points
hospital admission and discharge) and describe the preva-
ence of GI symptoms, the occurrence of GVHD and deaths up
o 100 days after transplantation (D + 100).
ethods
tudy  design  and  populationhis was a retrospective, descriptive and quantitative study
ased on clinical, and laboratory data and a review of the
utritional status of patients treated in a bone marrow 1 4;3  6(6):414–419 415
transplantation referral center in the city of Rio de Janeiro,
Brazil. Data were obtained from medical records from August
2010 to May 2013.
Patients aged 18 and older, of both genders, with neoplas-
tic or non-neoplastic diseases submitted to allogeneic HSCT
(related or unrelated) were included in the study. Patients with
previous history of HSCT and those whose medical records
were unavailable were excluded from the study.
Of the 76 patients who underwent allogeneic HSCT during
the study period, twelve were excluded from the study, seven
due to prior HSCT and ﬁve due to the lack of medical records.
Thus the study sample consisted of 64 patients.
Anthropometric parameters and laboratory data collected
are for two different time points, admission to the inpatient
unit for transplantation (T1) and unit discharge (T2). Clinical
parameters were collected from admission until 100 days after
transplant (D + 100). Data on the food intake and GI symptoms
refer to the hospitalization period.
The study was approved by the Ethics Committee of the
bone marrow transplantation referral center.
The following clinical data were investigated: diagnosis
of the underlying disease, comorbidities, type of transplant
(related or unrelated), source of HSC (bone marrow, peripheral
blood or umbilical cord blood), conditioning regimen, length
of hospitalization, time to engraftment, GI symptoms, use of
enteral nutrition (EN) and TPN, occurrence of GVHD and death.
Data on age, gender, education, ethnicity and lifestyle (smok-
ing and drinking) were also collected.
Laboratory tests included blood sugar, albumin, creatinine,
hemoglobin, hematocrit, potassium, phosphorus, magne-
sium, total bilirubin, direct bilirubin and C-reactive protein
(CRP) levels.
Moreover, anthropometric evaluations consisted of the
following indicators: current weight, usual weight, height,
percentage of weight loss and BMI. Nutritional status was clas-
siﬁed according to the BMI as: severe malnutrition (<16 kg/m2),
moderate malnutrition (16–16.9 kg/m2), mild malnutrition
(17–18.49 kg/m2), normal weight (18.5–24.9 kg/m2), overweight
(25–29.9 kg/m2), mildly obese (30–34.9 kg/m2), moderately
obese (35–39.9 kg/m2) or severely obese (>39.9 kg/m2).15 The
percentage of weight loss was calculated from the hospital
discharge weight and the admission weight.
The food intake was classiﬁed as low (<60%), partial (from
60% to 99%) or full (100%) based on the patient’s reported
intake on medical records. The classiﬁcation used is the one
standardized by the Department of Nutrition and Dietetics at
the Bone Marrow Transplantation center. Nausea, vomiting,
mucositis (Grades I to IV), odynophagia, hyporexia, diarrhea,
among other GI symptoms reported by patients during hospi-
talization were recorded.
Statistical  analysis
Descriptive analysis was performed, using the mean, median
and standard deviation for continuous variables and frequen-
cies for categorical variables. The Spearman correlation was
used to identify associations between nutritional status and
the clinical parameters of HSCT. The paired t-test was used
for comparisons between the time points (admission and
discharge) for variables with normal distribution, and the
oter.416  rev bras hematol hem
Wilcoxon signed-rank test and the Sign test were used for
non-parametric variables. The Statistical Program for Social
Sciences (SPSS version 22.0) was used for the statistical anal-
yses. The level of signiﬁcance was set at 5% for all statistical
tests.
Results
Socioeconomic  characteristics
The mean age of the patients was 42.1 ± 3.2 years, with 8%
of elderly (>60 years), and the distribution between males
and females was equal (50%). The percentage of smokers was
17.7% and 12.9% consumed alcohol. Skin color was predomi-
nantly white (46%) and brown (46%) and in terms of schooling
31% of patients had completed high school and 28% had uni-
versity degrees; there were no illiterate individuals in the
sample.
Clinical  characteristics  of  patients
Fifty-four patients (84.4%) underwent related and ten patients
(15.6%) unrelated allogeneic HSCT with the main source of
CTH being bone marrow (75%). The most common underly-
ing diseases were acute myeloid leukemia (39%) and chronic
myeloid leukemia (18.8%). There were prevalences of diabetes
mellitus (6%) and hypertension (13%).The main conditioning regimens and other clinical data are
shown in Table 1. The mean hospital stay was 36 ± 10 days. The
mean time to engraftment was 18.3 ± 6.6 days. The mortality
Table 1 – Clinical data and conditioning regimens.
n %
Type of HSCT
Related 54 84.4
Unrelated 10 15.6
Source of HSC
Bone marrow 48 75.0
Peripheral blood 13 20.3
Umbilical cord blood 2 3.1
Peripheral blood + bone marrow 1 1.6
Underlying disease
Acute myeloid leukemia 25 39.0
Chronic myeloid leukemia 12 18.8
Acute lymphoid leukemia 10 15.6
Myelodysplastic syndrome 8 12.5
Non-Hodgkin’s lymphoma 4 6.3
Aplastic anemia 4 6.3
Chronic lymphoid leukemia 1 1.5
Conditioning regimen
Bu-Cy 33 51.6
RCT-Cy 10 15.6
Bu-Flu 5 7.8
Cy-TBI-ATG 4 6.2
Others 12 18.8
Bu: busulfan; Cy: cyclophosphamide; TBI: total body irradiation; Flu:
ﬂudarabine; ATG: anti-thymocyte globulin; Mel: melphalan; Others:
Bu-Cy-ATG, Cy-ATG, Flu-Mel, Flu-Cy, Flu-ATG-Cy, Bu-Mel, Flu-Bu-
ATG, Cy. 2 0 1 4;3  6(6):414–419
rate by D + 100 was 34.4% (22 patients), with 50% of the deaths
occurring during hospitalization.
Of the 64 patients evaluated, 34 (53%) had GVHD before
D + 100. Among the patients with GVHD, the distribution
according to the organ involved was: skin (88%), GI tract
(73.5%), liver (47%); 11 patients (32%) had GVHD in three organs
(skin, gastrointestinal tract and liver).
Nutritional  assessment
On admission, the nutritional assessment according to the
BMI  showed that 29 patients had normal weight (45.3%), 23
were overweight (35.9%), eight mildly obese (12.5%), two  mod-
erately obese (3.1%), one had mild malnutrition (1.6%) and
one had moderate malnutrition (1.6%). Moreover, at this time
point, 10.4% of patients had suffered a weight loss > 5% of
usual weight. At discharge there was a further weight loss > 5%
compared to the weight at admission in 40.4% of cases.
Comparing the nutritional status of patients on admission
and at discharge (T1 vs. T2) the Wilcoxon signed-rank test
showed that there was a statistically signiﬁcant decrease in
the median weight (−2.5 kg; 71.5 vs. 68.75 kg; p-value < 0.001),
BMI  (−0.9 kg/m2; 24.8 vs. 24.4 kg/m2; p-value < 0.001), and
serum albumin level (−0.2 g/dL; 3.7 vs. 3.6 g/dL; p-value = 0.024)
(Table 2).
The serum albumin level at discharge was positively corre-
lated with survival time after HSCT (CC = 0.56; p-value = 0.004).
The serum total protein level at discharge also showed a
positive correlation with survival time after HSCT (CC = 0.53; p-
value = 0.006). On the other hand, the C-reactive protein level
at discharge showed a strong negative correlation with sur-
vival time after HSCT (CC = −0.72; p-value < 0.001).
Table 3 shows the characteristics of food intake and the
percentage of days of orally accepted food (low, partial or full),
fasting and TPN in relation to the total length of hospitaliza-
tion.
The distribution of GI symptoms reported by patients dur-
ing hospitalization is shown in Table 4.
Discussion
This study in addition to describing the nutritional proﬁle
of allogeneic HSCT patients also compared the nutritional
status of patients at admission and at discharge. Impaired
nutritional status is considered a negative prognostic factor
in hospitalized patients and is associated with adverse clinical
consequences.7,10
The mean length of hospitalization observed in this study
was similar to those previously reported by Bechard et al. (38
days)16 and Sommacal et al. (39 days).17 The median time
to engraftment in the current study was also similar to that
observed by Bechard et al. (20 days).
The mortality rate up to D + 100 in this study was 34%,
higher than that observed by Lee et al., 13 who reported 11.5%
of deaths until D + 100 in a sample of 315 allogeneic HSCT
patients.
Complications related to the transplantation include
the toxicity related to the conditioning regimen, the
medications used to control symptoms, infections and
rev bras hematol hemoter. 2 0 1 4;3  6(6):414–419 417
Table 2 – Comparison between anthropometric and laboratory variables of patients submitted to allogeneic HSCT at
admission (T1) and at discharge (T2).
Median Mean ± standard deviation p-Value
n T1 T2 Median difference
(T2 − T1)
T1  T2
Current weight (kg) 52 71.25 68.75 −2.5 70.50 ± 12.78 68.27 ± 11.82 0.000a
BMI (kg/m2) 52 24.80 24.40 −0.9 25.74 ± 4.85 24.97 ± 4.66 0.000a
Hemoglobin (g/dL) 48 10.80 9.55 −0.9 10.40  ± 2.37 9.64 ± 0.94 0.014b
Hematocrit (%) 48 32.95 28.40 −4.25  31.37 ± 7.48 28.33 ± 2.77 0.002a
Glycemia (mg/dL) 47 114.50 95.00 −13.5 147.92 ± 122.83 125.94 ± 91.85 0.041c
Albumin (g/dL) 47 3.70 3.60 −0.2 3.69 ± 0.53 3.52 ± 0.49 0.024a
Albumin/globulin 47 1.62 1.56 −0.15 1.70 ± 0.46 1.54 ± 0.36 0.005b
Total bilirubin (mg/dL) 47 0.34 0.53 0.19 0.40 ± 0.28 0.61 ± 0.39 0.000a
Direct bilirubin (mg/dL) 48 0.12 0.26 0.14 0.14 ± 0.12 0.33 ± 0.31 0.000a
Creatinine (mg/dL) 48 0.80 0.95 0.2 0.80 ± 0.25 1.04 ± 0.44 0.000a
Potassium (mg/dL) 48 4.10 4.50 0.4 4.10 ± 0.40 4.41 ± 0.61 0.005b
Phosphorus (mg/dL) 47 3.40 4.00 0.5 3.46 ± 0.65 3.95 ± 0.65 0.000a
Magnesium 48 2.30 1.70 −0.6 2.29 ± 0.47 1.69 ± 0.21 0.000a
CRP (mg/dL) 45 0.43 0.69 0.31 1.48 ± 2.60 1.57 ± 2.57 0.400a
T1: admission; T2: discharge; BMI: body mass index; CRP: C-reactive protein.
a Wilcoxon Signed-rank test.
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that the percentage of days on which the patient was  fasting
is lower, only 18.1%. This indicates that the TPN was associatedb Paired t-test.
c Sign test.
mmunosuppression, and also related to GVHD. In allogeneic
SCT, the serious side effects, including nausea, vomiting,
ucositis, diarrhea and hyporexia, impair food intake; these
ide effects can last for up to four weeks after HSCT.18,19
The frequency of acute toxicity related to HSCT, in this con-
ext represented by GI symptoms, was high however the high
ggressiveness of allogeneic transplantation should be con-
idered. In this study, over 90% of the sample had at least three
ymptoms of high nutritional impact (nausea – 100%, vomiting
 96.6%, and mucositis – 93.2%). With regard to the severity of
ucositis, 36% of patients developed Grade IV mucositis, thus
recluding the use of oral feeding.Dietary intake was affected greatly as can be seen by the
igh percentage of days of fasting (23.6 ± 17.4%) and TPN
42.9 ± 19.5%) and the low acceptance of food during a third
Table 3 – Characterization of food intake in days and
percentage of hospital stay.
Median Mean ± SD Range
Low intake (<60%)
n 11.0 11.9 ± 6.9 1.0–28.0
% 34.6 33.2 ± 17.7 4.3–77.0
Partial intake (60–99%)
n 12.0 13.5 ± 7.08 1.0–36.0
% 35.7 37.6 ± 19.9 2.1–76.9
Full intake (100%)
n 4.0 4.8 ± 3.6 1.0–19.0
% 10.7 13.6 ± 8.9 3.1–38.8
Fasting
n 6.0 10.3 ± 11.9 1.0–58.0
% 18.1 23.6 ± 17.4 2.9–68.1
TPN
n 17.0 18.2 ± 12.6 1.0–64.0
% 47.0 42.9 ± 19.5 4.4–81.4
SD: standard deviation; TPN: total parenteral nutrition.of the hospital stay. Several studies have reported that food
intake is signiﬁcantly compromised during the period of trans-
plantation mainly because of the side effects related to the
conditioning regimen.19
The food intake of patients throughout the hospital stay
was probably inﬂuenced by GI symptoms (Table 4). The mean
number of days with full food intake was only 13.6% of the
hospitalization period.
Among the patients studied, 62.7% received TPN, with a
median of 47% days on TPN. Hence, it is interesting to notewith oral ingestion most of the time.
Table 4 – Gastrointestinal symptoms during
hospitalization.
Symptoms %
Nausea 100.0
Vomiting 96.6
Mucositis 93.2
Grade I 10.9
Grade II 21.8
Grade III 29.1
Grade IV 36.4
Odynophagia 86.4
Hyporexia 78.0
Diarrhea 76.3
Abdominal pain 69.5
Epigastralgia 54.2
Syalorrhea 52.5
Abdominal distension 44.1
Gastric fullness 30.5
Heartburn 13.6
Dysgeusia 13.6
Xerostomia 6.8
Dysphagia 5.1
oter.
r418  rev bras hematol hem
Several studies comparing EN with TPN reported that the
use of nutritional therapy based on the GI tract is preferred
as it is a more  physiologic approach.20 Furthermore, TPN is
associated with an increased risk of infections, especially
in immunocompromised patients, which include patients
submitted to HSCT.13,20 However, in Allogeneic HSCT, most
patients progress to severe mucositis associated with throm-
bocytopenia, making EN less used in adult patients.
The percentage of patients with some degree of malnu-
trition on admission was only 3.1% and the percentage of
overweight/obesity was 51.5%. Sucak et al., in a study with
71 patients, found a similar distribution in relation to the
prevalence of malnutrition on admission (5.6%) but lower for
overweight/obesity (39.5%).21
The patients showed a worsening in their nutritional status
during hospitalization according to anthropometric (weight
loss and decrease in BMI) and laboratory parameters (decrease
in serum albumin levels). Body weight, as well as other
parameters, has limitations for nutritional assessment dur-
ing HSCT, especially in patients who use TPN as they can
have increased body water, thereby masking the real weight
loss.22
According to a survey of Japanese patients submitted to
allogeneic HSCT and evaluated by bioelectrical impedance,
more than half of the population (50.6%) had loss of mus-
cle mass before transplantation. These data suggest that the
nutritional status measured by weight and using BMI as a
parameter, could mask a loss of muscle mass and the accu-
mulation of fat mass.23
The nutritional status of patients during HSCT is not
well documented in the literature. Few studies have evalu-
ated the nutritional impact on adults of allogeneic HSCT.10,24
Park and Park evaluated the nutritional status before and
after allogeneic HSCT and observed a negative impact on
the nutritional status post-transplantation, but the relation-
ship of nutritional status on the outcome of HSCT was not
evaluated, for example, regarding the time of grafting or the
appearance of GI and/or clinical complications.25 Sucak et al.
observed a negative correlation between BMI  of patients sub-
mitted to allogeneic HSCT and the development of symptoms
and metabolic complications, such as mucositis, cardiotoxic-
ity and hyperglycemia.21
Some studies indicate that the nutritional status of
the patient before transplantation can affect the progno-
sis, and the extremes (malnutrition and obesity) are related
to higher mortality and more  complications associated
with transplantation.7,10 In this scenario, specialized nutri-
tional interventions may contribute to increased tolerance to
chemotherapy and radiotherapy, contributing to the success
of treatment.9,12,26
As in this study, Le Blanc, Ringdén and Remberger also
found no correlation between nutritional status and time of
neutrophil engraftment in patients submitted to allogeneic
transplantation.27 Hadjibabae et al. however found a signiﬁ-
cant delay in engraftment of neutrophils and platelets in low
weight patients submitted to allogeneic transplantation.22Most studies on the relationship between nutritional status
and post-transplant toxicity refer to adult patients submitted
to autologous transplantation, which is a treatment modality
relatively well tolerated in terms of toxicity. 2 0 1 4;3  6(6):414–419
Although the nutritional status does not present any major
impact on immunological complications or tumor behavior,
nutritional status may have an impact on the metabolism of
chemotherapeutic agents. The decreased levels of plasma pro-
teins and a reduced glomerular ﬁltration rate may increase the
free drug concentration and aggravate the cytotoxic effects in
patients with low weight.21
Furthermore, the altered nutritional status, particularly
malnutrition and obesity can have a negative impact on the
risk of infection, which is considered to be the main cause of
morbidity and mortality related to HSCT.8,21 Approximately
50% of patients remain with increased caloric and protein
needs up to one year after HSCT.10
Hosley, Bauer and Gallagher found that patients classiﬁed
as malnourished according to the Subjective Global Assess-
ment (SGA) validated for cancer patients had a BMI  within the
normal range (23.8 kg/m2).24 These results corroborate other
studies showing that cancer patients classiﬁed as normal or
overweight by BMI, could be classiﬁed as malnourished by
the SGA, thus suggesting that the body fat of these individ-
uals might be masking some degree of malnutrition not yet
revealed by the weight.28
Although this study presents some limitations related to
the sample size and the retrospective design, the results agree
with previous studies, reiterating the impairment of nutri-
tional status during the transplantation process.
Conclusion
Our results suggest that patients submitted to allogeneic HSCT
have a worsening in their nutritional status during hospital-
ization, mainly characterized by weight loss, high prevalence
of GI symptoms and low dietary intake, probably due to the
high toxicity related to this type of transplant and its compli-
cations. Thus it is important to analyze the factors involved in
causing the nutritional deﬁcits in order to implement early
nutritional intervention in patients submitted to allogeneic
HSCT.
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